Levetiracetam Aurovitas

Levetiracetam, the active ingredient in Levetiracetam Aurovitas, is an antiepileptic presented as an intravenous solution for intravenous use. It is employed to manage epilepsy, including partial‑onset and generalized tonic‑clonic seizures, in both adult and pediatric patients as prescribed by a healthcare professional.

GNH USA supplies Levetiracetam Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is manufactured under strict quality controls. It is distributed through GNH USA's global logistics network ensuring timely delivery.

Levetiracetam is an antiepileptic agent used to control seizure activity across several epilepsy syndromes.

Partial‑onset seizures: reduces frequency and severity of focal seizures when used as adjunct therapy. Generalized tonic‑clonic seizures: helps prevent convulsive episodes in patients with this seizure type. Epilepsy (broad): provides adjunctive treatment for patients with refractory seizures not controlled by other medications.

Levetiracetam may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness: mild vertigo or light‑headedness. - Fatigue: feeling unusually tired or weak. - Irritability: mood changes or agitation.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or breathing difficulty. - Suicidal thoughts: emergence of depressive symptoms or urges. - Hepatic dysfunction: abnormal liver enzymes or jaundice.

When prescribing levetiracetam, clinicians should consider several safety aspects. - Renal impairment: adjust dose in patients with reduced kidney function. - Hepatic disease: monitor liver function during therapy. - Concomitant CNS depressants: may enhance sedation. - Pregnancy: safety not established; weigh benefits vs risks. - Elderly: start at lower dose and titrate cautiously. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam levels. - Phenytoin: may increase risk of neurotoxicity. - Rifampin: may lower plasma concentration.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam exposure. - CNS depressants (e.g., benzodiazepines): additive sedation. - Alcohol: may enhance dizziness.